Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells $31,410.00 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the sale, the director now owns 74,438 shares of the company’s stock, valued at approximately $519,577.24. The trade was a 5.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Health Catalyst Stock Performance

HCAT stock opened at $7.08 on Friday. The company has a 50-day simple moving average of $7.96 and a 200 day simple moving average of $7.47. The company has a market capitalization of $430.80 million, a P/E ratio of -5.24 and a beta of 1.31. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the company posted ($0.22) earnings per share. The company’s revenue was up 3.5% on a year-over-year basis. Sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently modified their holdings of the company. Quest Partners LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at $34,000. Quarry LP lifted its holdings in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the last quarter. nVerses Capital LLC acquired a new stake in Health Catalyst in the 3rd quarter valued at about $59,000. Mackenzie Financial Corp bought a new position in shares of Health Catalyst during the 2nd quarter valued at about $70,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Health Catalyst in the 3rd quarter worth approximately $84,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HCAT has been the subject of a number of recent research reports. Evercore ISI boosted their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. JPMorgan Chase & Co. upped their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Royal Bank of Canada raised their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.